# Vamstar

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vamstar

- Industry: Healthcare IT
- Headquarters: London, UK
- Website: www.vamstar.io
- Total disclosed funding: $11M
- Latest round: Series A (Jun 22, 2022)
- Investors on record: 5

## About

Vamstar Limited, based in the UK, specializes in developing advanced AI-driven solutions for the MedTech, Pharma, and Biotech sectors, enhancing their operational efficiency and pricing strategies through innovative technologies.Founded in 2019, Vamstar Limited is headquartered in London, UK, and focuses on transforming how companies in the healthcare sector manage their tendering and pricing processes. The company was established by Praful Mehta and Richard Freeman, with Praful Mehta serving as CEO. Vamstar has successfully completed 3 deals, with its most recent funding round occurring on June 22, 2022, where it raised USD 9.5 mn in a Series A round led by Alpha Intelligence Capital and Dutch Founders Fund, alongside returning investors including Antler and b2venture. This funding has enabled Vamstar to enhance its capabilities and offerings in the market.Vamstar provides advanced AI-driven solutions tailored for the MedTech, Pharma, and Biotech sectors, focusing on enhancing commercial success through effective tendering, pricing, market access, and contract management. Their core offerings include an Agentic AI platform that automates processes such as RFP, RFQ, and tender analysis while integrating seamlessly into existing workflows. These solutions are designed to improve efficiency, bolster data intelligence, and optimize pricing strategies, ultimately delivering measurable impact on margin profiles for clients. Vamstar serves a diverse clientele, including leading global pharmaceutical companies, medical device manufacturers, and diagnostics organizations, with a presence in both local and international markets, particularly in Europe and North America.Vamstar operates on a revenue model that includes subscription-based services and partnerships with organizations within the healthcare sector. The company's flagship products, such as the AI-powered data orchestration engine and the Pricing Co-Pilot, facilitate B2B transactions, enabling clients to streamline their tendering and pricing processes. The structure of these transactions typically involves direct interactions with businesses, allowing for customized solutions based on the specific needs of clients. While the exact pricing plans for Vamstar’s offerings are not disclosed, the services are designed to provide significant value through enhanced operational efficiency and improved margin profiles for organizations in the life sciences industry.Following the completion of its Series A funding on June 22, 2022, where Vamstar raised USD 9.5 mn, the company plans to accelerate its market and product development initiatives. Vamstar is focused on designing and launching new products to enhance their service offerings in the healthcare sector. Specific markets for expansion include additional regions across Europe and North America, with goals to establish a stronger presence by the end of 2023. This recent funding will support these growth strategies by allowing Vamstar to enhance their product capabilities and reach more clients effectively.

## Funding rounds

- Series A, Jun 22, 2022, $9.5M — b2venture, Alpha Intelligence Capital, Antler, Dutch Founders Fund
- Seed, Dec 4, 2020, $1.3M — b2venture, Antler, Begin Capital Partners

## Investors

- b2venture (https://capitalatlas.ai/funds/b2venture) — Seed, Series A
- Antler (https://capitalatlas.ai/funds/antler) — Seed, Series A
- Begin Capital Partners (https://capitalatlas.ai/funds/begin-capital-partners) — Seed
- Alpha Intelligence Capital (https://capitalatlas.ai/funds/alpha-intelligence-capital) — Series A
- Dutch Founders Fund (https://capitalatlas.ai/funds/dutch-founders-fund) — Series A